of next-generation sequencing into routine medical practice. 48
The recently introduced CADD[3] scores are a promising alternative [4] . These are 49 calculated on the output of multiple in silico tools in combination with other genomic features. 50
They trained a computer model on variants that have either been under long-term selective 51 evolutionary pressure or none at all. The result was an estimation of deleteriousness for variants 52 in the human genome, whether already observed or not. It has been shown to be a strong and 53 versatile predictor for pathogenicity [3] . These scores may be used to define a classifier that labels 54 a variant with a CADD score of >15 as probably pathogenic and <15 as benign, as suggested by 55 the CADD authors [5] . Unfortunately, clinicians and laboratories cannot rely on this single 3 threshold approach. We have shown that individual genes differ in their cut-off thresholds for what 57 should be considered the optimal boundary between pathogenic or benign [4] . This issue has 58 been partly addressed by MSC[6] (Mutation Significance Cutoff), which provides gene-based 59 CADD cut-off values to remove inconsequential variants safely from sequencing data. While MSC 60 aims to quickly and reliably reduce the number of benign variants left to interpret, it was not 61 developed to detect/classify pathogenic variants. 62
The challenge is thus to find robust algorithms that classify both pathogenic and benign 63 variants accurately and that fit into existing best practice, diagnostic filtering protocols [7] . 64 Implementing such tools is not trivial because genes have different levels of tolerance to various 65 classes of variants that may be considered harmful [8] . In addition, the pathogenicity estimates for 66 benign variants are intrinsically lower because these are more common and of less severe 67 consequence on protein transcription. Comparing the prediction score distributions of pathogenic 68 variants with those of typical benign variants is therefore biased and questionable. Using such an 69 approach means it will be unclear how well a predictor truly performs if a benign variant shares 70 many properties with known pathogenic variants. Here, we present GAVIN (Gene-Aware Variant 71 INterpretation), a new method that addresses these issues by gene-specific calibrations on 72 closely matched sets of variants. GAVIN SnpEff, ExAC and CADD prior to classification by GAVIN. To assess the clinical relevance of our 103 method, we stratified the combined set into clinically relevant variant subsets based on organ-104 system specific genes. We formed 19 subset panels such as Cardiovascular, Dermatologic, and 105
Oncologic based on the gene-associated physical manifestation categories from Clinical 106 Genomics Database [13] . A total of 11,679 out of 25,765 variants were not linked to clinically 107 characterized genes and formed a separate panel (see Table 2 for an overview). In addition, we 108 assessed the performance of GAVIN in compared to 12 common in silico tools for pathogenicity 109 We illustrated the practical implications of classification sensitivity and specificity in Table  121 4. Here, 90%/80% represents the performance of GAVIN, 90%/60% matches CADD, and 122 70%/80% or 70%/60% can be considered averages of other methods. In a hypothetical example 123
where 110 variants are being tested (100 benign and 10 pathogenic), the difference in predictive 124 value between the performance opposites is over two-fold (31% positive predictive value (PPV) 125 for 90/80% and 15% PPV for 70/60%). 126 127
Added value of gene-specific calibration 128
We then investigated the added value of using gene-specific thresholds on classification 129 performance relative to using genome-wide thresholds. We bootstrapped the performance on 130 10,000 random samples of 100 benign and 100 pathogenic variants. These variants were drawn 131 from the three groups of genes described in Materials & Methods: (1) genes for which CADD 132 was significantly predictive for pathogenicity (n = 520), (2) genes where CADD was not 133 significantly predictive (n = 660), and (3) genes with scarce variant data available for calibration 134 (n = 737). For each of these sets we compared the use of gene-specific CADD and MAF 135 classification thresholds with that of genome-wide filtering rules (CADD score < 15 and MAF > 136 0.00474 for benign, otherwise classify as pathogenic). 137
We observed the highest accuracy on genes for which CADD had significant predictive 138 value and for the gene-specific classification method (median accuracy = 87.5%); this was 139 significantly higher than using the genome-wide method for these same genes (median accuracy 6 = 85%, Mann-Whitney U test p-value < 2.2e-16). For genes for which CADD had less predictive 141 value we found a lower overall performance, but still reached a significantly better result using the 142 gene-specific approach (median accuracy = 84.5% versus genome-wide 82%, p-value < 2.2e-143 16). Lastly, the worst performance was seen for variants in genes with scarce training data 144 available. The gene-specific performance, however, was still significantly better than using 145 genome-wide thresholds (median accuracy = 83.5% and 81% respectively, p-value = 2.2e-16). We have developed GAVIN, a method for automated variant classification using gene-specific 150 calibration of classification thresholds for benign and pathogenic variants. 151
Our results show that GAVIN is a powerful classifier with consistently high performance in 152 clinically relevant genes. The robustness of our method arises from a calibration strategy that first 153 corrects for calibration bias between benign and pathogenic variants, in terms of consequence 154 and rarity, before calculating the classification thresholds. A comprehensive benchmark 155 demonstrates a unique combination of high sensitivity (>90%) and high specificity (>70%) for 156 variants in genes related to different organ systems. This is a significant improvement over 157 existing tools that tend to achieve either a high sensitivity (CADD, MSC) or a high specificity 158
(PredictSNP2). A high sensitivity is crucial for clinical interpretation because pathogenic variants 159
should not be falsely discarded. In addition, having a higher specificity means that the results will 160 be far less 'polluted' with false-positives and thus less risk of patients being given a wrong 161 molecular diagnosis. GAVIN decreases false-positives by about 20% compared to using CADD 162 for the same purpose, thereby reducing the interpretation time considerably. The difference 163 between using a high and low performance method can be dramatic in practice. In a hypothetical 164 example, GAVIN would make downstream variant interpretation twice as effective as a low 165 performance method, with more sensitive detection of pathogenic variants. 166
Even though an optimal combination of sensitivity and specificity may be favorable in 167 general terms, there may still be a need for tools that perform differently. The MSC gene-specific 7 thresholds based on HGMD[24] at 99% confidence interval show a very high sensitivity (97.1%), 169 but at the expense of a very low specificity (25.7%). Such low specificity thresholds will pick up 170 almost all the pathogenic variants with scores exceeding gene thresholds. This allows safe 171 removal (<3% error) of benign variants that fall below these thresholds, which was their authors' 172 aim. However, this tool cannot detect pathogenic variants due its low specificity. Other tools, such 173 as PON-P2, may show a relatively low performance, but not necessarily because of true errors. 174
Such tools may simply be very 'picky' and only return a classification when the verdict carries 175 high confidence. If we ignore the variants that PON-P2 did not classify, and only consider how 176 many of the variants that it did classify were correct, we find a positive predictive value of 96%, 177 and a negative predictive value of 94%. Thus, while this tool might not be useful for exome 178 screening because too many pathogenic variants would be lost, it can still be an excellent choice 179 for further investigation of interesting variants. We would therefore emphasize that appropriate 180 tools should be selected depending on the question or analysis protocol used and by taking their 181 strengths and weaknesses into account. 182
Not surprisingly, we could confirm that the use of gene-specific thresholds instead of 183 genome-wide thresholds led to a consistent and significant improvement of classification 184 performance. This shows the added value of our strategy. Overall performance was slightly lower 185 in genes for which CADD has limited predictive value, and even lower in genes with few 'gold 186 standard' pathogenicity data available. Evaluating variants in uncharacterized genes is rare in 187 clinical diagnostics, although it may occur when exome sequencing is aimed at solving complex 188 phenotypes or undiagnosed cases. Nevertheless, GAVIN is likely to improve continuously in an 189 increasing number of genes, propelled by the speed at which pathogenic variants are now being 190
reported. 191
With GAVIN we were also able to demonstrate the residual power of CADD scores as a 192 predictor for pathogenicity on a gene-by-gene basis, revealing that the scores are informative for 193 many genes (these results can be accessed at http://molgenis.org/gavin). reference set of reasonable quantity becomes available, a calibration strategy as described here 208 will be essential to be able to use these metrics effectively in whole-genome diagnostics. 209 210 CONCLUSIONS 211 GAVIN provides an automated decision-support protocol for classifying variants, which will 212 continue to improve in scope and precision as more data is publicly shared by genome diagnostic 213 laboratories. Our approach bridges the gap between estimates of genome-wide and population-214 wide variant pathogenicity and contributes to their practical usefulness for interpreting clinical 215 variants in specific patient populations. Databases such as ClinVar contain a wealth of implicit 216 rules now used manually by human experts to classify variants. These rules are deduced and 217 employed by GAVIN to classify variants that have not been seen before. 218
We envision GAVIN accelerating NGS diagnostics and becoming particularly beneficial 219 as a powerful (clinical) exome screening tool. It can be used to quickly and effectively detect over 220 90% of pathogenic variants in a given data set and to present these results with an 221 unprecedented small number of false-positives. It may especially serve laboratories that lack the 222 resources necessary to perform reliable and large-scale manual variant interpretation for their 223 patients, and spur the development of more advanced gene-specific classification methods. We 
Calibration of gene-specific thresholds 231
We downloaded ClinVar (variant_summary.txt.gz from ClinVar FTP, last modified date: 05/11/15) 232 and selected GRCh37 variants that contained the word "pathogenic" in their clinical significance. 233
These variants were matched against the ClinVar VCF release (clinvar.vcf.gz, last modified date: 234 01/10/15) using RS (Reference SNP) identifiers in order to resolve missing indel notations. On 235 the resulting VCF, we ran SnpEff version 4.1L with these settings: hg19 -noStats -noLog -lof -236 canon -ud 0. As a benign reference set, we selected variants from ExAC (release 0.3, all sites) 237 from the same genic regions with +/-100 bases of padding on each side to capture more variants 238 residing on the same exon. 239
We first determined the thresholds for gene-specific pathogenic allele frequency by taking 240 the ExAC allele frequency of each pathogenic variant, or assigning zero if the variant was not 241 present in ExAC, and calculating the 95 th percentile value per gene using the R7 method from 242 Apache Commons Math version 3.5. We filtered the set of benign variants with this threshold to 243 retain only variants that were rare enough to fall into the pathogenic frequency range. 244
Following this step, the pathogenic impact distribution was calculated as the relative 245 proportion of the generalized effect impact categories, as annotated by SnpEff on the pathogenic 246 variants. The same calculation was performed for the benign variants using the variant Ensembl 247 VEP[33] consequence types already present in ExAC. To facilitate this, we defined a trivial 248 mapping of VEP consequences types (being equivalent to SnpEff consequences) to SnpEff 249 impact categories. The benign variants were subsequently downsized to match the impact 250 distribution of the pathogenic variants. 251
For instance, in the case of 407 pathogenic MYH7 variants, we found a pathogenic allele 252 frequency threshold of 9.494e-05, and an impact distribution of 5.41% HIGH, 77.4% 253 MODERATE, 17.2% LOW and 0% MODIFIER. We defined a matching set of benign variants by 254 retrieving 1,799 MYH7 variants from ExAC (impact distribution: 2.1% HIGH, 23.52% 255 MODERATE, 32.07% LOW, 42.32% MODIFIER), from which we excluded known ClinVar 256 pathogenic variants (n = 99), variants above the AF threshold (n = 377), and removed 257 interspersed variants using a non-random 'step over' algorithm until the impact distribution was 258 equalized (n = 862). We thus reached an equalized set of 461 variants. This process was 259 repeated for 3,055 genes. 260
We then obtained the CADD scores for all variants and tested whether there was a 261 significant difference in scores between the sets of pathogenic and benign variants for each gene, 262 using a Mann-Whitney U test. Per gene we determined the mean CADD score for each group, 263 and also the 95 th percentile sensitivity threshold (detection of most pathogenic variants while 264 accepting false-positives) and 95 th percentile specificity threshold (detection of most benign 265 variants while accepting false-negatives), using the Percentile R7 function. All statistics were 266 done with Apache Commons Math version 3.5. 267
On average, CADD scores were informative of pathogenicity. The mean benign variant 268 CADD score across all genes was 23.68, while the mean pathogenic variant CADD score was 269
28.45, a mean difference of 4.77 (σ = 4.69). Of 3,055 genes that underwent the calibration 270 process, we found 520 "CADD predictive" genes that had a significantly higher CADD score for 271 pathogenic variants than for benign variants (Mann-Whitney U test, p-value <0.05). Interestingly, 272 we also found 660 "CADD less predictive" genes, for which there was no proven difference 273 between benign and pathogenic variants (p-value >0. 05 We obtained six variant sets that had been classified by human experts. These data sets were 285 used to benchmark the in silico variant pathogenicity prediction tools mentioned in this paper. 286
Variants from the original sets may sometimes be lost due to conversion of cDNA/HGVS notation 287 We selected 1,688 pathogenic variants from ClinVar that were added between November 299 2015 and February 2016 as an additional benchmarking set, since our method was based on the 300 November 2015 release of ClinVar. We supplemented this set with a random selection of 1,668 301 benign variants from ClinVar, yielding a total of 3,356 variants. 302
We obtained an in-house list of 2,359 variants that had been classified by molecular and 303 clinical geneticists at the University Medical Center Groningen. These variants belong to patients 304 seen in the context of various disorders: cardiomyopathies, epilepsy, dystonia, preconception 305 carrier screening, and dermatology. Variants were analyzed according to Dutch medical center 306 guidelines[36] for variant interpretation, using Cartagenia Bench Lab TM (Agilent Technologies)
GoNL[38]), functional effect and literature searches. Any ClinVar variants included in the 310
November 2015 release were removed from this set to prevent circular reasoning, resulting in a 311 total of 1,512 variants, with 1,176 benign/likely benign (merged as Benign), 162 VUS, and 174 312 pathogenic/likely pathogenic (merged as Pathogenic). 313
From the UMCG diagnostics laboratory we also obtained a list of 607 variants seen in the 314 context of familial cancers. These were interpreted by a medical doctor according to ACMG 315 guidelines [7] . We removed any ClinVar variants (November 2015 release), resulting in 395 316 variants, with 301 benign/likely benign (merged as Benign), 68 VUS and 26 likely 317 pathogenic/pathogenic (merged as Pathogenic). 318 319
Variant data processing and preparation 320
We used Ensembl VEP (http://grch37.ensembl.org/Homo_sapiens/Tools/VEP/) to convert 321 cDNA/HGVS notations to VCF format. Newly introduced N-notated reference bases were 322 replaced with the appropriate GRCh37 base, and alleles were trimmed where needed (e.g. 323 "TA/TTA" to "T/TT"). We annotated with SnpEff (version 4.2) using the following settings: hg19 -324 noStats -noLog -lof -canon -ud 0. CADD scores (version 1.3) were added by running the variants 325 through the CADD webservice (available at http://cadd.gs.washington.edu/score). ExAC (release 326 0.3) allele frequencies were added with MOLGENIS annotator (release 1.16.2). We also merged 327 all benchmarking sets into a combined file with 25,995 variants (of which 25,765 classified as 328 benign, likely benign, likely pathogenic or pathogenic) for submission to various online in silico 329 prediction tools. 330 331
Execution of in silico predictors 332
The combined set of 25,765 variants was classified by the in silico variant pathogenicity 333 predictors (MSC, CADD, SIFT, PolyPhen2, PROVEAN, Condel, PON-P2, PredictSNP2, 334 compared the observed output to the expected classification and which then calculated 336 performance metrics such as sensitivity and specificity. The tools that we evaluated and the web 337 addresses used can be found in Supplementary Table 2 . We executed PROVEAN and SIFT, for 338 which the output was reduced by retaining the following columns: "INPUT", "PROVEAN 339 PREDICTION (cut-off = -2.5)" and "SIFT PREDICTION (cut-off = 0.05)". For PONP-2, the output 340 was left as-is. The Mutation Significance Cutoff (MSC) thresholds are configurable; we 341 downloaded the ClinVar-based thresholds for CADD 1.3 at 95% confidence interval, comparable 342 to our method, as well as HGMD-based thresholds at 99% confidence interval, the default setting. 343
Variants below the gene-specific thresholds were considered benign, and above the threshold 344 pathogenic. We obtained CADD scores of version 1.3. Following the suggestion of the CADD 345 authors, scores of variants below a threshold of 15 were considered benign, above this threshold 346 pathogenic. The output of Condel was reduced by retaining the following columns: "CHR", 347 "START", "SYMBOL", "REF", "ALT", "MA", "FATHMM", "CONDEL", "CONDEL_LABEL". After 348 running PolyPhen2, its output was reduced by retaining the positional information 349 ("chr2:220285283|CG") and the "prediction" column. Finally, we executed PredictSNP2, which 350 contains the output from multiple tools. From the output VCF, we used the INFO fields "PSNPE", 351 "FATE", "GWAVAE", "DANNE" and "FUNE" for the pathogenicity estimation outcomes according thresholds in three groups of genes: 520 genes for which CADD is predictive, 660 genes for 543 which CADD is less predictive, and 737 genes with scarce training data. For each group, 10,000 544 sets of 100 benign and 100 pathogenic variants were randomly sampled and tested from the full 545 set of 25,765 variants and accuracy was calculated for gene-specific and genome-wide CADD 546 and MAF thresholds. 547 548 549 Variant and classification origins of the benchmark data sets used. The practical impact in clinical diagnostics of using methods of different sensitivity and specificity 563 on a data set with 100 benign and 10 pathogenic variants. 564 565 Supplementary Table 1 . 566
Detailed overview of all benchmark results. Each combination of tool and data set is listed. We 567 provide the raw counts of true-positives (TP), true-negatives (TN), false-positives (FP) and false-568 negatives (FN), as well as of pathogenic and benign variants that were 'missed', i.e. not correctly 569 identified as such. From these numbers we calculated the sensitivity and specificity. 570 571 Supplementary Table 2 . 572
The tools used to evaluate our benchmark variant set, and the web addresses used through 573 which they were accessed. 574
